Equities

E-Therapeutics PLC

ETX:LSE

E-Therapeutics PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)9.80
  • Today's Change0.20 / 2.08%
  • Shares traded2.33m
  • 1 Year change-27.27%
  • Beta-0.2280
Data delayed at least 20 minutes, as of Apr 26 2024 16:35 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year E-Therapeutics PLC had relatively flat revenues (477.00k to 475.00k), though the company grew net income from a loss of 8.07m to a smaller loss of 8.27m. A reduction in the selling, general and administrative costs as a percentage of sales from 785.12% to 636.21% was a component in the net income growth despite flat revenues.
Gross margin100.00%
Net profit margin-1,741.90%
Operating margin-2,155.58%
Return on assets-25.79%
Return on equity-27.23%
Return on investment-27.10%
More ▼

Cash flow in GBPView more

In 2023, E-Therapeutics PLC increased its cash reserves by 179.30%, or 20.34m. Cash Flow from Investing totalled 15.31m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 8.01m for operations while cash generated from financing totalled 13.05m.
Cash flow per share-0.0145
Price/Cash flow per share--
Book value per share0.0568
Tangible book value per share0.0564
More ▼

Balance sheet in GBPView more

E-Therapeutics PLC appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio21.30
Quick ratio--
Total debt/total equity0.0089
Total debt/total capital0.0089
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.